or Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC ...

Rhythm Pharmaceuticals, Inc.’s RYTM share price has dipped by 10.71%, which has investors questioning if this is right time to buy.

or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. Both the European Commission ...

In Europe and the UK, Imcivree is approved for patients aged two and older with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency.

As Healio previously reported, setmelanotide (Imcivree, Rhythm Pharmaceuticals) is a melanocortin-4 receptor agonist that the FDA approved for individuals with pro-opiomelanocortin (POMC ...